|
| Status |
Public on Mar 04, 2019 |
| Title |
Patient D3 |
| Sample type |
SRA |
| |
|
| Source name |
CDK4/6 inhibitor treated patient biopsy
|
| Organism |
Homo sapiens |
| Characteristics |
sample type: Tissue
cdk4/6 inhibitor phenotype: Intrinsic Resistance
|
| Treatment protocol |
All patients were treated with a CDK4/6
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Qiagen's AllPrep DNA/RNA/miRNA Universal
NEBNext® Small RNA Library Prep Set for Illumina, as per manufacturers instructions
|
| |
|
| Library strategy |
miRNA-Seq |
| Library source |
transcriptomic |
| Library selection |
size fractionation |
| Instrument model |
Illumina NextSeq 500 |
| |
|
| Description |
RNA derived from CDK4/6 inhibitor treated patient biopsy
|
| Data processing |
Raw counts were normalised to Counts per million. CPM was used for direct comparisons between patient phenotypes. Genome_build: hg19
|
| |
|
| Submission date |
Jul 26, 2018 |
| Last update date |
Mar 04, 2019 |
| Contact name |
Liam Cornell |
| E-mail(s) |
liam_cornell@dfci.harvard.edu
|
| Organization name |
Dana-Farber Cancer Institute
|
| Street address |
450 brookline avenue
|
| City |
boston |
| State/province |
MASSACHUSETTS |
| ZIP/Postal code |
02215 |
| Country |
USA |
| |
|
| Platform ID |
GPL18573 |
| Series (2) |
| GSE117747 |
MicroRNA-mediated suppression of the TGF-β pathway confers transmissible and reversible CDK4/6 inhibitor resistance (miRNA-Seq) |
| GSE117748 |
MicroRNA-mediated suppression of the TGF-β pathway confers transmissible and reversible CDK4/6 inhibitor resistance |
|
| Relations |
| BioSample |
SAMN09725045 |
| SRA |
SRX4474120 |
